Metabolites, derived from microbes or the host, encompass a diverse range of small molecules that play vital roles in regulating fundamental processes in healthy and malignant cells. Given the vast number of metabolites involved, the utilization of cutting-edge technologies available at The M3 Research Center is pivotal for studying and unraveling the functions of these highly relevant molecules under steady-state conditions and in the context of cancer. In addition, our research aims to identify substances which dampen or enhance therapy response representing a new stepping stone for cancer therapies.
Malignom and Metabolome
Immune signatures of chronic inflammatory human diseases driving cancer
Prof. Dr. Mathias Heikenwälder
Head of the research group
The laboratory of Mathias Heikenwälder aims at understanding the different immune signatures of chronic inflammatory human diseases driving cancer - with the final aim to generate appropriate mouse models used for pre-clinical research and translation into the clinic.
frontend.sr-only_: More about the group
Mechanisms involved in cancer development
Prof. Dr. Nisar Peter Malek
Head of the research group
Our group investigates mechanisms involved in cancer development including cell cycle control, DNA damage and repair, and ER stress.
frontend.sr-only_: More about the group
Lifestyle Interventions in Metabolic Diseases and Cancer
Dr. Suchira Gallage
Head of the research group
Our group focuses on uncovering the cellular and molecular mechanisms governing complex metabolic diseases and cancer with an emphasis on lifestyle interventions and/or combinatorial drug treatments.
frontend.sr-only_: More about the group
Tumor immune microenvironment
Dr. med. Benjamin Ruf
Head of the research group
In our lab, we aim to expand our knowledge of the composition, phenotype, and organization of the tumor immune microenvironment (TiME) in gastrointestinal cancers with the goal to ultimately improve patient care.
frontend.sr-only_: More about the group
Microbiome-immune interactions
Dr. Lukas Mager
Head of the research group
Our research aims at studying the impact of microbiome-immune interactions on the development, progression, and treatment of inflammatory bowel disease (IBD) and colorectal cancer (CRC).
frontend.sr-only_: More about the group
Immunomonitoring & Cancer Immunology
PD Dr. rer. nat. Kilian Wistuba-Hamprecht
Head of the research group
A major focus of our research is the investigation of role and function of γδ T cells in cancer rejection.
frontend.sr-only_: More about the group
Post-transcriptional control in metastasis
Dr. rer. med. Pavlos Missios
Head of the research group
Our research group investigates the impact of post-transcriptional gene regulation mediated by microRNAs (miRNAs) and RNA-binding proteins (RBPs) on the development of metastases.
frontend.sr-only_: More about the group
Novel treatment options for liver cancer
Dr. Verena Wagner
Head of the research group
Our goal is to identify new vulnerabilities of tumor cells and to exploit them therapeutically.
frontend.sr-only_: More about the group
Gastrointestinal Oncology and Personalized Medicine
Prof. Dr. med. Michael Bitzer
Head of the research group
Our group engages in both translational and clinical research in gastrointestinal oncology and personalized medicine.
frontend.sr-only_: More about the group